A 66-year-old man with metastatic non-small cell lung cancer is brought to the emergency d… — USMLE Step 3

A 66-year-old man with metastatic non-small cell lung cancer is brought to the emergency department by his husband due to extreme lethargy, nausea, and intermittent confusion over the past four days. He has lost $4.5 \text{ kg}$ ( $9.9 \text{ lbs}$ ) over the last month. His current oncologic regimen includes a monoclonal antibody targeting programmed cell death protein 1 (PD-1), which he has received every three weeks for the past four months. On presentation, his temperature is $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure is $86/52 \text{ mmHg}$ , and heart rate is $112\text{ /min}$ . Physical examination reveals delayed capillary refill and generalized weakness.

Initial laboratory studies show:

Laboratory Parameter	Patient Value	Reference Range
Sodium	$131 \text{ mEq/L}$	$136-145 \text{ mEq/L}$
Potassium	$4.1 \text{ mEq/L}$	$3.5-5.0 \text{ mEq/L}$
Glucose	$62 \text{ mg/dL}$	$70-100 \text{ mg/dL}$
TSH	$0.05 \ \mu\text{U/mL}$	$0.4-4.0 \ \mu\text{U/mL}$
Free T4	$0.5 \text{ ng/dL}$	$0.9-2.4 \text{ ng/dL}$
Morning cortisol	$1.8 \ \mu\text{g/dL}$	$10-20 \ \mu\text{g/dL}$
Plasma ACTH	$4 \text{ pg/mL}$	$10-60 \text{ pg/mL}$

Based on the patient's presentation and laboratory findings, which of the following best characterizes the fundamental immunopathologic event precipitating this patient's acute clinical deterioration?

Disruption of peripheral immune tolerance resulting in T-lymphocyte-mediated destruction of the anterior pituitary glandCevap
B
Production of inhibitory autoantibodies that competitively block melanocortin receptors in the adrenal cortex
C
Excessive release of pro-inflammatory cytokines triggering systemic capillary leak and bilateral adrenal hemorrhage
D
Immune complex deposition activating the classical complement cascade within the hypothalamic-pituitary microvasculature
E
Impaired central tolerance due to failure of negative selection allowing escape of autoreactive CD4+ and CD8+ thymocytes

Cevap

The correct answer is the disruption of peripheral immune tolerance resulting in T-lymphocyte-mediated destruction of the anterior pituitary gland.

The correct answer identifies the disruption of peripheral tolerance. Pembrolizumab is an immune checkpoint inhibitor targeting the Programmed Cell Death Protein 1 (PD-1) receptor. Under normal physiologic conditions, the binding of PD-1 to its ligand (PD-L1) downregulates T-cell activation in peripheral tissues. This is a critical mechanism for maintaining peripheral immune tolerance and preventing autoimmunity. By therapeutically blocking PD-1, the patient's immune system successfully attacks tumor cells but simultaneously loses peripheral tolerance to self-antigens. This unrestrained T-lymphocyte activation can lead to severe immune-related adverse events (irAEs), including autoimmune hypophysitis. The patient's laboratory profile (hyponatremia, hypoglycemia, normal potassium, low cortisol, low ACTH, low TSH, and low Free T4) is pathognomonic for secondary adrenal insufficiency and central hypothyroidism resulting from inflammatory destruction of the anterior pituitary gland.

Adım Adım Çözüm

Analyze the patient's vital signs and basic metabolic panel.

The patient is in shock (hypotensive, tachycardic) with hyponatremia and hypoglycemia, highly suggestive of an adrenal crisis.

Cortisol is critical for vascular tone and gluconeogenesis; its absence leads to shock and hypoglycemia.

Interpret the endocrine laboratory profile.

Low morning cortisol with an inappropriately low ACTH indicates secondary (central) adrenal insufficiency. Additionally, low free T4 with a low TSH indicates central hypothyroidism. Together, this localizes the pathology to the anterior pituitary gland (panhypopituitarism).

In primary adrenal insufficiency, ACTH would be elevated due to the loss of negative feedback. In central disease, the pituitary fails to produce the stimulating hormones.

Connect the clinical diagnosis to the patient's medication history.

The patient is receiving a PD-1 inhibitor (pembrolizumab). Immune checkpoint inhibitors are strongly associated with immune-related adverse events (irAEs), prominently including autoimmune hypophysitis.

Recognizing drug-induced toxicities is crucial in modern oncology.

Determine the exact immunologic mechanism of the medication causing the adverse event.

PD-1 is an inhibitory receptor on T cells that binds PD-L1 on tissues to induce T-cell exhaustion, thereby maintaining peripheral tolerance. Blocking this pathway unleashes cytotoxic T cells, leading to autoimmune destruction of tissues like the pituitary.

Understanding the distinction between peripheral tolerance (PD-1 pathway) and central tolerance (thymic negative selection) isolates the correct answer.

Anahtar Kavram

Immune checkpoint inhibitors (such as anti-PD-1 agents) block inhibitory signaling pathways that normally maintain peripheral tolerance, which can lead to unrestrained T-cell activation and subsequent immune-related adverse events, including autoimmune hypophysitis.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru